Fabiana Martins Kattah

Ms. Fabiana Martins Kattah

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2021 in Cytokine
Verified
Journal Article
Closed access
RLRafael S. Lima
Rafael S. Lima
RMRafael T. Mattos
Rafael T. Mattos
NMNayara I. Medeiros
Nayara I. Medeiros
FKFabiana Martins Kattah
Fabiana Martins Kattah
JNJulya R.S. Nascimento
Julya R.S. Nascimento
PMPaula R. Moreira
Paula R. Moreira

3 October 2024 in Biomedicines
Verified
Journal Article
Open access
PDF file
GLGislene Batista Lima
Gislene Batista Lima
NFNayra Figueiredo
Nayra Figueiredo
FKFabiana Martins Kattah
Fabiana Martins Kattah
EOEMILLY SANTOS OLIVEIRA
EMILLY SANTOS OLIVEIRA
MHMaria Aderuza Horst
Maria Aderuza Horst
FCFlavia Campos Corgosinho
Flavia Campos Corgosinho
Background: Inflammation plays a central role in many chronic diseases that characterize modern society. Leptin/adiponectin and adiponectin/leptin ratios have been recognized as notable markers of dysfunctional adipose tissue and, consequently, an inflammatory state. Methods: Blood samples were collected from 41 adult volunteers (40.2 ± 8.3 years) diagnosed with severe obesity (BMI 46.99; 42.98–51.91 kg/m2). The adipokines were quantified using an enzyme-linked immunosorbent assay, while the serum fatty acid analysis was conducted using chromatography. Results: The results unveiled a positive correlation between the leptin/adiponectin ratio and the 20:3n6 fatty acid (r = 0.52, p = 0.001), as well as a similar positive correlation between the adiponectin/leptin ratio and the 22:6n3 fatty acid (r = 0.74, p = 0.001). In the regression analysis, the 22:6n3 fatty acid predicted the adiponectin/leptin ratio (β = 0.76, p < 0.001), whereas C20:3 n-6 was a predictor for inflammatory markers (β = 4.84, p < 0.001). Conclusions: In conclusion, the 22:6n3 fatty acid was demonstrated to be a predictive factor for the adiponectin/leptin ratio and C20:3 n-6 was a predictor for inflammatory markers. This discovery, novel within this population, can help develop new intervention strategies aimed at controlling the inflammatory status in individuals classified as having severe obesity.

31 May 2024 in Biomedicines
Verified
Journal Article
Open access
PDF file
FKFabiana Martins Kattah
Fabiana Martins Kattah
MJMilijana Janjusevic
Milijana Janjusevic
NFNayra Figueiredo
Nayra Figueiredo
EOEMILLY SANTOS OLIVEIRA
EMILLY SANTOS OLIVEIRA
GLGlaucia Carielo Lima
Glaucia Carielo Lima
FCFlavia Campos Corgosinho
Flavia Campos Corgosinho
Background: Obesity is a chronic inflammatory disorder that increases the risk of cardiovascular diseases (CVDs). Given the high CVD mortality rate among individuals with obesity, early screening should be considered. Plasminogen activator inhibitor (PAI-1), a cytokine that links obesity and CVDs, represents a promising biomarker. However, PAI-1 is not part of the clinical routine due to its high cost. Therefore, it is necessary to find good predictors that would allow an indirect assessment of PAI-1. Methods: This study enrolled 47 women with severe obesity (SO). The obtained anthropometric measurements included weight, height, neck (NC), waist (WC), and hip circumference (HC). Blood samples were collected to analyse glucose and lipid profiles, C-reactive protein, liver markers, adiponectin, and PAI-1 (determined by ELISA immunoassay). Homeostasis model assessment-adiponectin (HOMA-AD), homeostasis model assessment of insulin resistance (HOMA-IR), quantitative insulin sensitivity check index (QUICKI), triglyceride–glucose index (TyG), and atherogenic index of plasma (AIP) were calculated. The women were grouped according to PAI-1 levels. The data were analysed using IBM SPSS Statistics, version 21. The significance level for the analysis was set at 5%. Results: Women with SO who have higher levels of PAI-1 have lower values of high-density lipoprotein cholesterol (HDL) (p = 0.037) and QUICKI (0.020) and higher values of HOMA-AD (0.046) and HOMA-IR (0.037). HOMA-IR was demonstrated to be a good predictor of PAI-1 in this sample (B = 0.2791; p = 0.017). Conclusions: HOMA-IR could be used as a predictor of PAI-1 levels, pointing out the relevance of assessing glycaemic parameters for the prevention of CVDs in women with SO.

15 January 2026 in Obesity Reviews
Verified
Journal Article
Open access
ADANA RAIMUNDA DÂMASO
ANA RAIMUNDA DÂMASO
FCFlavia Campos Corgosinho
Flavia Campos Corgosinho
DMDEBORAH CRISTINA LANDI MASQUIO
DEBORAH CRISTINA LANDI MASQUIO
NFNayra Figueiredo
Nayra Figueiredo
FKFabiana Martins Kattah
Fabiana Martins Kattah
RCRaquel Munhoz da Silveira Campos
Raquel Munhoz da Silveira Campos
Obesity as a chronic and multifactorial disease requires a multidisciplinary team acting together in a holistic multitarget intervention. Multidisciplinary therapy targeting obesity and its complications includes physical exercise, nutritional, and behavior counseling. When lifestyle changes are not sufficient in adults, medication prescription and bariatric surgery may be recommended. The aim of this narrative review is to summarize the underlying mechanisms and effects of multidisciplinary therapy in the control of obesity and its complications in adults. [Correction added on 21 January 2026, after first online publication: The previous sentence has been corrected in this version.] All types of clinical studies developed in an adult population were included. Different types of multidisciplinary therapy (short‐ and long‐term) in the primary and secondary settings were identified. Multidisciplinary therapy seems to be useful in the control of adverse effects of obesity, including reductions in biomarkers of inflammation, cardiometabolic risk factors, dyslipidemia, diabetes, hypertension, metabolic syndrome, nonalcoholic fatty liver diseases, atherosclerosis, cardiovascular disease, obstructive sleep apnea, and psychosocial outcomes. These results highlight the importance of targeting obesity and its complications in a holistic approach with a multidisciplinary team acting together.

20 June 2025 in Nutrients
Verified
Journal Article
Open access
PDF file
FKFabiana Martins Kattah
Fabiana Martins Kattah
NFNayra Figueiredo
Nayra Figueiredo
KBKamilla Kenned Bezerra
Kamilla Kenned Bezerra
EOEMILLY SANTOS OLIVEIRA
EMILLY SANTOS OLIVEIRA
CMCinara Costa de Melo
Cinara Costa de Melo
FCFlavia Campos Corgosinho
Flavia Campos Corgosinho
Gastrointestinal symptoms, including reflux, bloating, dyspepsia, stomach pain, and altered bowel patterns, are commonly reported in individuals with severe obesity and may significantly impact quality of life. Background/Objectives: Curcumin, a bioactive compound found in turmeric (Curcuma longa L.), possesses anti-inflammatory and antioxidant properties and has been investigated for its potential role in gastrointestinal health. However, its effects in individuals with severe obesity remain unclear. Methods: This double-blind, placebo-controlled clinical trial aimed to evaluate the effect of curcumin supplementation on gastrointestinal symptoms in women with severe obesity. Thirty-one women with a body mass index (BMI) ≥ 40 kg/m2 undergoing bariatric surgery were randomized to receive either 1500 mg of curcumin (98.75%) or a placebo (1500 mg corn starch) daily for 13 weeks. Gastrointestinal symptoms were assessed using the Gastrointestinal Symptom Rating Scale (GSRS), and stool consistency was assessed using the Bristol Stool Scale. Anthropometric measurements were also collected. Results: Participants had an average age of 33.1 ± 8 years and a BMI of 45.6 ± 3.31 kg/m2. No differences were observed between groups at baseline. At the end of the study, the curcumin group showed a significant reduction in the GSRS’s total score compared to the placebo group (p = 0.002), with improvements in eructation (p = 0.011) and constipation (p = 0.007). Additionally, the curcumin group showed reduced BMI (p = 0.019) and neck circumference (p = 0.042). Conclusions: These findings suggest that curcumin supplementation may alleviate some gastrointestinal symptoms and improve anthropometric measures in women with severe obesity, providing a potential dietary strategy.

1 June 2024 in Clinical Nutrition ESPEN
Verified
Journal Article
Closed access
FKFabiana Martins Kattah
Fabiana Martins Kattah
EOEmilly Santos Oliveira
Emilly Santos Oliveira
NFNayra Figueiredo
Nayra Figueiredo
CMCinara Costa de Melo
Cinara Costa de Melo
BBBeatriz Bacheschi Do Carmo Benetti
Beatriz Bacheschi Do Carmo Benetti
FCFlavia Campos Corgosinho
Flavia Campos Corgosinho